Jump to main content
Jump to site search

Issue 7, 2008
Previous Article Next Article

Isoform-selective histone deacetylase inhibitors

Author affiliations

Abstract

Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes. This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors. The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.

Graphical abstract: Isoform-selective histone deacetylase inhibitors

Back to tab navigation

Publication details

The article was received on 05 Mar 2008 and first published on 08 May 2008


Article type: Tutorial Review
DOI: 10.1039/B703830P
Citation: Chem. Soc. Rev., 2008,37, 1402-1413
  •   Request permissions

    Isoform-selective histone deacetylase inhibitors

    A. V. Bieliauskas and M. K. H. Pflum, Chem. Soc. Rev., 2008, 37, 1402
    DOI: 10.1039/B703830P

Search articles by author

Spotlight

Advertisements